Compare compounds

Survodutide

Vials

10 / 20 mg

Dosing data

Lab reference — not listed

Retatrutide

Start

2 mg

Range

2–12 mg

Frequency

Once weekly

Cycle

Ongoing, titrated every 4 weeks

Vials

10 / 20 / 30 mg

Titration

1. Weeks 1–4: 2 mg
2. Weeks 5–8: 4 mg
3. Weeks 9–12: 8 mg
4. Weeks 13+: 12 mg (highest trial arm)

Survodutide

Survodutide is a dual agonist of the glucagon and GLP-1 receptors, studied for weight and liver-fat effects.

Retatrutide

Retatrutide (LY3437943) is a single peptide agonist of three receptors: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity is studied for increasing energy expenditure and liver-fat effects on top of the appetite effects of GIP/GLP-1 agonism.

Survodutide

• Phase 2 obesity trial (387 adults, 46 weeks): mean weight change of −6.2% to −14.9% across arms vs −2.8% with placebo.
• Phase 2 MASH trial: MASH improvement without worsening fibrosis in 43%–62% across arms vs 14% with placebo.

Retatrutide

• Phase 2 obesity trial (338 adults): mean weight change at 48 weeks ranged from −8.7% to −24.2% across arms vs −2.1% with placebo.
• In the highest arm, 83% of participants lost 15% or more of body weight at 48 weeks, vs 2% on placebo.
• Preclinical and early clinical work describes glycaemic and weight effects from combined triple-receptor agonism.

Survodutide

• Investigational: not approved by the FDA or EMA; phase 3 trials are ongoing.
• Adverse events were mainly gastrointestinal (75% vs 42% on placebo in the obesity trial); in the MASH trial nausea 66% vs 23% and vomiting 41% vs 4%.

Retatrutide

• Investigational: not approved by the FDA or EMA for any indication. Phase 3 trials are ongoing.
• Phase 2 adverse events were mainly gastrointestinal and dose-related; heart-rate increases were also reported.

Survodutide

2 references · view

Retatrutide

2 references · view